Limited efficacy of daratumumab in multiple myeloma with
extramedullary disease

J 2022

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

JELINEK, Tomas, Tereza SEVCIKOVA, David ZIHALA, Tereza POPKOVA, Veronika KAPUSTOVA et. al.

Basic information

Original name

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

Authors

JELINEK, Tomas (203 Czech Republic, guarantor), Tereza SEVCIKOVA (203 Czech Republic), David ZIHALA (203 Czech Republic), Tereza POPKOVA (203 Czech Republic), Veronika KAPUSTOVA (203 Czech Republic), Lucie BROSKEVICOVA (203 Czech Republic), Lenka CAPKOVA (203 Czech Republic), Lucie ŘÍHOVÁ (203 Czech Republic), Renata BEZDĚKOVÁ (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Vladimir ZIDLIK (203 Czech Republic), Martin HAVEL (203 Czech Republic), Hana PLONKOVA (203 Czech Republic), Alexandra JUNGOVA (203 Czech Republic), Jiri MINARIK (203 Czech Republic), Martin ŠTORK (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), Petr PAVLICEK (203 Czech Republic), Ivan SPICKA (203 Czech Republic), Vladimir MAISNAR (203 Czech Republic), Jakub RADOCHA (203 Czech Republic), Michal SIMICEK (203 Czech Republic) and Roman HAJEK (203 Czech Republic)

Edition

Leukemia, London, Nature Publishing Group, 2022, 0887-6924

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 11.400

RIV identification code

RIV/00216224:14110/22:00124970

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1038/s41375-021-01343-w

UT WoS

000671626300001

Keywords in English

daratumumab; multiple myeloma; extramedullary disease; efficacy

Abstract

V originále

The treatment of multiple myeloma (MM) has changed substantially during the past two decades. The incorporation of novel agents into therapeutic strategies has resulted in prolonged overall survival of MM patients with approximately 15% of them being considered operationally cured.

Links

LM2018140, research and development project

Name: e-Infrastruktura CZ (Acronym: e-INFRA CZ)

Investor: Ministry of Education, Youth and Sports of the CR

NV17-29343A, research and development project

Name: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu

Citovat

JELINEK, Tomas, Tereza SEVCIKOVA, David ZIHALA, Tereza POPKOVA, Veronika KAPUSTOVA, Lucie BROSKEVICOVA, Lenka CAPKOVA, Lucie ŘÍHOVÁ, Renata BEZDĚKOVÁ, Sabina ŠEVČÍKOVÁ, Vladimir ZIDLIK, Martin HAVEL, Hana PLONKOVA, Alexandra JUNGOVA, Jiri MINARIK, Martin ŠTORK, Luděk POUR, Petr PAVLICEK, Ivan SPICKA, Vladimir MAISNAR, Jakub RADOCHA, Michal SIMICEK and Roman HAJEK. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. London: Nature Publishing Group, 2022, vol. 36, No 1, p. 288-291. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01343-w.

@article{1787325,
   author = {Jelinek, Tomas and Sevcikova, Tereza and Zihala, David and Popkova, Tereza and Kapustova, Veronika and Broskevicova, Lucie and Capkova, Lenka and Říhová, Lucie and Bezděková, Renata and Ševčíková, Sabina and Zidlik, Vladimir and Havel, Martin and Plonkova, Hana and Jungova, Alexandra and Minarik, Jiri and Štork, Martin and Pour, Luděk and Pavlicek, Petr and Spicka, Ivan and Maisnar, Vladimir and Radocha, Jakub and Simicek, Michal and Hajek, Roman},
   article_location = {London},
   article_number = {1},
   doi = {http://dx.doi.org/10.1038/s41375-021-01343-w},
   keywords = {daratumumab; multiple myeloma; extramedullary disease; efficacy},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Limited efficacy of daratumumab in multiple myeloma with extramedullary disease},
   url = {https://www.nature.com/articles/s41375-021-01343-w},
   volume = {36},
   year = {2022}
}

TY  - JOUR
ID  - 1787325
AU  - Jelinek, Tomas - Sevcikova, Tereza - Zihala, David - Popkova, Tereza - Kapustova, Veronika - Broskevicova, Lucie - Capkova, Lenka - Říhová, Lucie - Bezděková, Renata - Ševčíková, Sabina - Zidlik, Vladimir - Havel, Martin - Plonkova, Hana - Jungova, Alexandra - Minarik, Jiri - Štork, Martin - Pour, Luděk - Pavlicek, Petr - Spicka, Ivan - Maisnar, Vladimir - Radocha, Jakub - Simicek, Michal - Hajek, Roman
PY  - 2022
TI  - Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
JF  - Leukemia
VL  - 36
IS  - 1
SP  - 288-291
EP  - 288-291
PB  - Nature Publishing Group
SN  - 08876924
KW  - daratumumab
KW  - multiple myeloma
KW  - extramedullary disease
KW  - efficacy
UR  - https://www.nature.com/articles/s41375-021-01343-w
N2  - The treatment of multiple myeloma (MM) has changed substantially during the past two decades. The incorporation of novel agents into therapeutic strategies has resulted in prolonged overall survival of MM patients with approximately 15% of them being considered operationally cured.
ER  -

JELINEK, Tomas, Tereza SEVCIKOVA, David ZIHALA, Tereza POPKOVA, Veronika KAPUSTOVA, Lucie BROSKEVICOVA, Lenka CAPKOVA, Lucie ŘÍHOVÁ, Renata BEZDĚKOVÁ, Sabina ŠEVČÍKOVÁ, Vladimir ZIDLIK, Martin HAVEL, Hana PLONKOVA, Alexandra JUNGOVA, Jiri MINARIK, Martin ŠTORK, Luděk POUR, Petr PAVLICEK, Ivan SPICKA, Vladimir MAISNAR, Jakub RADOCHA, Michal SIMICEK and Roman HAJEK. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. \textit{Leukemia}. London: Nature Publishing Group, 2022, vol.~36, No~1, p.~288-291. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01343-w.

Detailed Information on Publication Record